Post by Deleted on Mar 19, 2011 15:58:55 GMT -5
Abstract
Thirty pet ferrets with adrenocortical disease (ACD) of varying severity and duration were
evaluated for response to a single administration of a slow release 4.7 mg deslorelin acetate
implant. Clinical response to deslorelin was monitored via a physical examination performed every 3 to 4 months. Adrenal ultrasound measurements were taken every 3-4
months until clinical relapse. At clinical relapse, duration of symptom suppression and
adrenal size and growth were determined. Administration of a single 4.7 mg implant of
deslorelin acetate resulted in significant decreases in the clinical signs and hormonal
concentrations associated with ACD. Within 14 days post-implant, vulvar swelling, pruritus,
sexual behaviors and aggression decreased or disappeared. Hair re-growth was evident by
4-6 weeks post implant. Within two months post deslorelin implant, plasma concentrations
of steroid hormones decreased: mean estradiol concentration decreased 28%; 17-hydroxyprogesterone levels decreased 89% and androstenedione levels decreased 88%. The
response to a single 4.7 mg implant of deslorelin acetate was transitory. The mean SD
time to recurrence of clinical signs was 17.6 +/- 5.0 months (range, 8.0-30.0 months).
Repeated ultrasound measurements revealed no statistical difference in size of the adrenals (right or left) before, during the months of deslorelin implant and at clinical relapse.
Slow release 4.7 mg deslorelin implants can effectively be used to temporarily eliminate the
clinical signs and reduce steroid hormone concentrations in ferrets with ACD. This dose of
deslorelin does appear to influence adrenal tumor growth causing a decrease in adrenal
size in some ferrets, and mild enlargement of adrenal glands in most ferrets with 2 of 30
implanted animals developing large tumors before clinical relapse. The long-term
effect of treatment with deslorelin on adrenal tumor pathology requires additional
investigation. At this time, surgical removal of the adrenal tumor remains the only
curative treatment; however, 4.7 mg deslorelin implants are useful in the long-term
management of ACD hormone-induced sequelae and may be as effective assurgical
management.
Full PDF is attached
Thirty pet ferrets with adrenocortical disease (ACD) of varying severity and duration were
evaluated for response to a single administration of a slow release 4.7 mg deslorelin acetate
implant. Clinical response to deslorelin was monitored via a physical examination performed every 3 to 4 months. Adrenal ultrasound measurements were taken every 3-4
months until clinical relapse. At clinical relapse, duration of symptom suppression and
adrenal size and growth were determined. Administration of a single 4.7 mg implant of
deslorelin acetate resulted in significant decreases in the clinical signs and hormonal
concentrations associated with ACD. Within 14 days post-implant, vulvar swelling, pruritus,
sexual behaviors and aggression decreased or disappeared. Hair re-growth was evident by
4-6 weeks post implant. Within two months post deslorelin implant, plasma concentrations
of steroid hormones decreased: mean estradiol concentration decreased 28%; 17-hydroxyprogesterone levels decreased 89% and androstenedione levels decreased 88%. The
response to a single 4.7 mg implant of deslorelin acetate was transitory. The mean SD
time to recurrence of clinical signs was 17.6 +/- 5.0 months (range, 8.0-30.0 months).
Repeated ultrasound measurements revealed no statistical difference in size of the adrenals (right or left) before, during the months of deslorelin implant and at clinical relapse.
Slow release 4.7 mg deslorelin implants can effectively be used to temporarily eliminate the
clinical signs and reduce steroid hormone concentrations in ferrets with ACD. This dose of
deslorelin does appear to influence adrenal tumor growth causing a decrease in adrenal
size in some ferrets, and mild enlargement of adrenal glands in most ferrets with 2 of 30
implanted animals developing large tumors before clinical relapse. The long-term
effect of treatment with deslorelin on adrenal tumor pathology requires additional
investigation. At this time, surgical removal of the adrenal tumor remains the only
curative treatment; however, 4.7 mg deslorelin implants are useful in the long-term
management of ACD hormone-induced sequelae and may be as effective assurgical
management.
Full PDF is attached
Attachments:
